Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta-Analysis With Reconstructed Time-to-Event and Trial Sequential Analysis
Department
Internal Medicine
Document Type
Article
Publication Title
Journal of Cardiovascular Electrophysiology
Abstract
BACKGROUND: Ventricular tachycardia (VT) is a major contributor to sudden cardiac death among patients with ischemic heart disease (IHD). While catheter ablation reduces the arrhythmic burden, the impact on long-term outcomes remains uncertain. We assess the efficacy of catheter ablation in patients with IHD.
METHODS: We performed a meta-analysis by systematically searching electronic databases from inception to April 2025. Pairwise, reconstructed time-to-event data meta-analyses and Trial Sequential analyses were conducted.
RESULTS: A total of seven studies (1192 participants) were included. Among patients with IHD with ICD, VT ablation was associated with a significant reduction in ICD shocks (RR = 0.50, 95% CI = [0.34-0.74]), a trend toward reduced VT storm (RR = 0.64, 95% CI = [0.40-1.04], p = 0.07), and lower rates of cardiovascular hospitalization (RR = 0.73, 95% CI = [0.53-1.01], p = 0.06) compared to ICD alone. However, no significant differences were observed when compared to patients receiving ICD plus antiarrhythmic drugs (AADs). VT ablation showed no significant impact on mortality or VT/VF recurrence compared to either ICD alone or ICD with AADs. Reconstructed Kaplan-Meier analysis for all-cause mortality showed no significant difference between VT ablation and AAD + ICD. Trial Sequential Analysis provided conclusive evidence for VT/VF recurrence, while further data is required for other outcomes.
CONCLUSION: Among patients with IHD with ICD, VT ablation reduces ICD shocks, VT storm, and cardiovascular hospitalizations compared to ICD-only therapy, but offers no significant advantage over ICD combined with AADs. VT ablation does not impact overall mortality or the recurrence of VT/VF. Trial sequential analysis confirmed conclusive evidence for VT/VF recurrence, while additional data is needed for other outcomes.
First Page
2934
Last Page
2949
DOI
10.1111/jce.70075
Volume
36
Issue
11
Publication Date
11-1-2025
Publisher
Futura Pub.
Medical Subject Headings
Humans; Tachycardia, Ventricular; Catheter Ablation; Myocardial Ischemia; Treatment Outcome; Time Factors; Male; Middle Aged; Female; Cardiomyopathies; Risk Factors; Aged; Defibrillators, Implantable; Electric Countershock; Risk Assessment; Heart Rate; Recurrence; Action Potentials; Death, Sudden, Cardiac
PubMed ID
40958137
Recommended Citation
Elbenawi, H., Ayman, Y., Hashim, A., Agarwal, S., Wagdy, M., Hamed, B. M., Thakurathi, P., Al-Shammari, A. S., Mohamed, K. A., Kalaiger, A. M., Ibrahim, A., Eisa, M., Ibrahim, R., Zaaya, M., Tan, M., Almaadawy, O., Quelal, K., Asad, Z. U., Lee, J. Z., Siontis, K., Arenal, Á., Del-Carpio Munoz, F., DeSimone, C. V., & Deshmukh, A. J. (2025). Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta-Analysis With Reconstructed Time-to-Event and Trial Sequential Analysis. Journal of Cardiovascular Electrophysiology, 36 (11), 2934-2949. https://doi.org/10.1111/jce.70075